The cancer center will begin offering the treatment, which targets and destroys the prostate cancer specific biomarker PSMA+, in March, according to a Feb. 18 news release from Providence.
Previously, the treatment has been available only in the lower 48 states, the release said.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
